Simple blood tests may help predict ovarian cancer treatment success
NCT ID NCT07678008
First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This study investigates whether certain blood-based markers, such as the neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and the CA-125 elimination rate (KELIM score), can predict survival and surgical outcomes in women with advanced ovarian cancer. Researchers will review medical records of 80 patients who received chemotherapy before surgery. The goal is to see if these markers can help forecast how long patients live without the disease worsening and whether surgery will be successful.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors better predict which patients with advanced ovarian cancer will respond to chemotherapy and surgery, potentially guiding more personalized treatment plans.
- What could go wrong
- This is a small, retrospective study, so results may not apply to all patients. The markers studied are not yet proven to be reliable enough for routine clinical use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OVARIAN CANCER (STAGE III OR IV) AFTER NEOADJUVANT CHEMOTHERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sohag university hospital
Sohag, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug cocktail aims to shrink recurrent ovarian tumors
- New drug combo aims to improve ovarian cancer maintenance with fewer dropouts
- New mRNA vaccine aims to stop ovarian Cancer's return
- New drug combo targets tough ovarian cancers
- Scientists track immune clues in breast and ovarian tumors
- Ovarian cancer gene hunt: 300 patients to shape future therapies